dronabinol has been researched along with Sclerosis, Systemic in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 2 (66.67) | 2.80 |
Authors | Studies |
---|---|
Bloom, BJ; Chung, L; Constantine, S; de Vries-Bouwstra, J; Denton, CP; Dgetluck, N; Dinh, Q; Distler, O; Finzel, S; Frech, TM; Furst, DE; Gordon, J; Hsu, V; Hummers, L; Jankowski, T; Jun, JB; Kafaja, S; Khanna, D; Kuwana, M; Lee, EB; Leszcyzński, P; Levy, Y; Litinsky, I; Matucci-Cerinic, M; Mayes, M; Sandorfi, N; Simms, RW; Spiera, R; Steen, V; Stevens, W; White, B | 1 |
Chung, L; Constantine, S; Dgetluck, N; Domsic, R; Frech, TM; Furst, DE; Gordon, J; Hsu, V; Hummers, L; Lafyatis, R; Lee, E; Martyanov, V; Mayes, M; Simms, R; Spiera, R; White, B; Whitfield, ML; Wood, T | 1 |
Akhmetshina, A; Baldi, C; Balistreri, E; Capecchi, PL; Distler, JH; Galeazzi, M; Gianchecchi, E; Gonzalez, EG; Lazzerini, PE; Lorenzini, S; Lucattelli, M; Montilli, C; Palumbo, K; Pasini, FL; Selvi, E | 1 |
2 trial(s) available for dronabinol and Sclerosis, Systemic
Article | Year |
---|---|
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
Topics: Cannabinoid Receptor Agonists; Dronabinol; Humans; Scleroderma, Diffuse; Scleroderma, Systemic; Severity of Illness Index; Skin; Treatment Outcome | 2023 |
Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis.
Topics: Adolescent; Adult; Aged; Cannabinoid Receptor Agonists; Double-Blind Method; Dronabinol; Drugs, Investigational; Female; Humans; Male; Middle Aged; Receptor, Cannabinoid, CB2; Scleroderma, Systemic; Severity of Illness Index; Skin; Synthetic Drugs; Treatment Outcome; Young Adult | 2020 |
1 other study(ies) available for dronabinol and Sclerosis, Systemic
Article | Year |
---|---|
Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis.
Topics: Adult; Aged; Animals; Cannabinoids; Collagen; Disease Models, Animal; Dronabinol; Female; Fibroblasts; Fibrosis; Humans; Male; Mice; Middle Aged; Scleroderma, Systemic | 2012 |